Big Pharma manages symptoms. This startup resolves the root cause.

For over 125 years, inflammation care has relied on symptom suppression.

Aspirin was groundbreaking in its time — but in a world plagued by chronic inflammation — we all need something better.

​Sen-Jam​ is pioneering the first true leapfrog advance in inflammatory care.

Q: What do cancer, heart disease, and rheumatoid arthritis have in common? A: Inflammation drives them all.

Inflammation is a silent epidemic, at the core of countless chronic diseases. Yet today’s treatments only mask symptoms or worse suppress the body’s immune system, leaving the root cause untouched.

Sen-Jam changes that.

With its revolutionary ​PAIR (Pleiotropic Anti-Inflammatory Remedies)​ technology, Sen-Jam comprehensively targets inflammation at its source, delivering the most transformative advance since aspirin was invented.

This isn’t just an improvement—it’s a paradigm shift.

How does Sen-Jam work?

Most therapies target single inflammatory pathways — like fighting a wildfire with a squirt gun 🔥🔫

PAIR acts like a maestro, coordinating multiple inflammatory pathways for additive, powerful results.

In a Phase 2 clinical trial for SJP-002C, PAIR demonstrated:

• Strong efficacy in treating respiratory inflammation

• An exceptional safety profile, addressing both symptoms and roo causes.

“Our approach is so simple and powerful, it’s like discovering the next aspirin — an essential solution that changes everything.

Why invest in Sen-Jam?

• Massive TAM: Inflammation underlies a wide range of diseases, driving a $125 billion market projected by 2030.

• Unprecedented Innovation: 60 patents strong, Sen-Jam’s groundbreaking platform is positioned to disrupt the $1.48T pharma industry.

• Past successful exits: Backed by a team of scientific experts and entrepreneurial veterans with a proven track record.

“This is the inflection point. Science, timing, and market demand have aligned for the biggest advance in 125 years.

Perks of investing

• Invest any amount and get ​Fractional Royalty Rights​ as annual dividends

• Bonus Incentives for Larger Investments:

  • $25k+: 10% bonus in stock

  • $50k+: 12% bonus in stock

  • $100k+: 14% bonus in stock

Note: these favorable terms sunset February 15th

Be part of the next breakthrough in healthcare.

Express interest

Click the button below to:

1. Gain access to exclusive updates

2. Take your place in shaping the future of healthcare

3. Invest in the most transformative advance in over a century

The future of inflammation care starts now.

Transform health. Transform lives. Transform your portfolio.

To learn more about Sen-Jam without giving permission to email, ​click here​.

📰 Market Headlines

Markets whipsawed yesterday as President Trump's tariff threats rattled North American trade.

• The Dow rose nearly 0.4%, the S&P 500 gained 0.5%, and the Nasdaq rose 0.3%.

• Tech stocks were in focus, with Meta and Tesla rising 1.6% and 2.9%, respectively.

The CAD and Peso plummeted over a percent after President Trump announced a 25% tariff on Canadian and Mexican imports.

President Trump blamed diversity initiatives for undermining air safety as the probe began into the deadly midair collision near DC.

Apple's China sales dropped 11.1% last quarter due to inventory issues and competition from local brands like Huawei.

🧠 Make yourself heard

Quiz time…don’t cheat.

 📊 Ideas, trends, and analysis

• The 30-year mortgage rate dipped to 6.95% but remains high, offering little relief for spring buyers.

😱 Fear and Greed Index

📊 Winners and losers

Earnings, upgrades, and acquisitions

• Apple reported Q1 earnings with a 5% net income rise; shares dropped 0.8%.

• Blackstone had its price target adjusted following acquisition uncertainty; shares fell 4%.

• Caterpillar reported a 7% revenue increase in 2024; shares dropped 4.6%.

• Comcast released record quarterly results with a 46% jump in Peacock revenue; shares plummeted 11%.

• After some skepticism, Intel reported a steady Q4; shares ended up 1.3%.

• Mastercard reported better-than-expected Q4 results with a 20% increase in earnings; shares rose 3.1%.

Market movers

• OpenAI entered talks for a $40 billion investment round, valuing the company at $340 billion.

• Costco raised hourly pay for most US store workers to over $30, starting with $30.20 this year.

• US lawmakers pressed the Trump administration to restrict Nvidia chip exports to Chinese AI firm DeepSeek.

• Blackstone vowed to maintain its data center investments despite market turbulence from DeepSeek's emergence.

• UPS announced it would reduce Amazon deliveries by over 50%.

• Ironwood Pharmaceuticals slashed 50% of its workforce after disappointing 2025 guidance.

🎤 What you said last time

What You Had to Say:
“What does IBM even do anymore? I can't name a single IBM product.”

📺 What to Watch Today